Aim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG-PETCT)-derived markers of tumour metabolism have been reported to have prognostic significance in a variety of tumours. Host inflammation is also recognized to have prognostic significance. The aim of the present study was to investigate the relationship between these markers and host systemic inflammation in patients undergoing elective surgery for colorectal cancer.
Introduction
Colorectal cancer is one of the most common malignancies in the Western world [1] . It is now well understood that the host systemic inflammatory response, evaluated using the modified Glasgow Prognostic Score (mGPS) [2] and neutrophil-lymphocyte ratio (NLR) [3] , is an important prognostic factor in patients with either primary operable or advanced inoperable cancer. However, the nature of the link between the systemic inflammatory response and the primary or secondary tumour is poorly understood. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG-PETCT) is a nuclear medicine imaging technique based on the relative uptake of glucose. The radioactive tracer is taken up by cells as glucose would normally be, and the positrons emitted are detected by the PET scanner. The spatial distribution of metabolic activity derived from PET is coregistered with CT to provide an accurate anatomical location of increased glucose uptake. It can be used in staging, monitoring the response to neoadjuvant therapy and detecting loco-regional recurrence or metastases in patients with colorectal cancer [4, 5] . 18 F-FDG-PETCT measures the net glucose uptake in tumours and provides objective data on tumour glucose metabolism. In patients with colorectal cancer, higher glucose metabolism, as determined by 18 F-FDG-PETCT, has been associated with markers of tumour proliferation [6, 7] , a lower likelihood of down-staging following neoadjuvant chemoradiotherapy [8] and long-term survival [9] [10] [11] .
More recently, 18 F-FDG-PETCT parameters have been shown to be associated with long-term use of antiinflammatories in patients with colorectal cancer [12] , and with preoperative systemic inflammation in patients with lung cancer [13] . Based on these recent findings, we hypothesized that the host systemic inflammatory response may be associated with tumour metabolism.
Therefore, the aim of the present study was to investigate the relationship between the 18 F-FDG-PETCTderived markers of tumour metabolism, in both primary and recurrent colorectal cancer, and host systemic inflammation in patients who underwent surgery for colorectal cancer.
Method Patients
Patients with histologically confirmed colorectal cancer who underwent elective, potentially curative surgery between February 2008 and April 2015 and who also underwent 18 F-FDG-PETCT during their treatment, either prior to surgery or as part of their follow-up after surgery, at a single centre, were included in the study. Patients had routine blood sampling including a full blood count (FBC), serum C-reactive protein (CRP) and albumin concentration at the time of 18 F-FDG-PETCT. It was found that 18 F-FDG-PETCT scans had been performed in two groups of patients. The first group were patients imaged during preoperative staging prior to surgery, in whom 18 F-FDG-PETCT parameters were measured from the primary colonic or rectal lesion. The second group were patients imaged during postoperative follow-up at the request of the colorectal multidisciplinary team meeting (MDT) who were found to have probable recurrent disease in CT and/or MRI imaging, and in whom 18 F-FDG-PETCT parameters were measured from the recurrent or dominant metastatic lesion. 
Method
Clinicopathological data were collected prospectively in a database, anonymized and subsequently analysed. 18 F-FDG-PETCT images were retrospectively analysed by a consultant nuclear medicine physician blind to the clinical outcomes, mGPS or NLR. Recorded information included patient demographics and clinicopathological, operative and radiological ( 18 F-FDG-PETCT) data.
Recorded 18 F-FDG-PETCT parameters included maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), metabolic tumour volume and total lesion glycolysis. Serum concentrations of CRP (mg/l) were measured using an autoanalyser (Architect, Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/l, as was serum albumin (normal range 35-50 g/l). The neutrophil-lymphocyte ratio was calculated for each patient for whom neutrophil and lymphocyte counts were available [3] . The modified Glasgow Prognostic Score (mGPS) was calculated in patients for whom serum CRP and albumin concentrations were available [2] .
F-FDG-PETCT
18 F-fluorodeoxyglucose positron emission tomographycomputed tomography scanning was performed according to our department's standard procedures based on the European Association of Nuclear Medicine guidelines [15] . Patients were fasted for at least 6 h before and 1 h after the intravenous injection of 400 MBq 18 F-FDG.
Blood glucose levels were measured before 18 F-FDG injection to ensure concentrations of < 11 mmol/l. 710; General Electric System, Milwaukee, Wisconsin, USA). Unenhanced CT images were acquired using a 120-kV automatic mA modulation range of 15-240 mAs. The torso CT covered from skull base to midthigh, with reconstructions performed at 2.5-mm increments. This was followed by PET images, encompassing the same transverse field of view as the CT. PET acquisition time was 3-4 min per bed position. PET attenuation correction was based on the CT data, and images were corrected for scatter and iteratively reconstructed using time of flight and SharpIR on a 192 9 192 matrix. PETCT images were analysed on GE Advantage Workstation using a SUVmax of 7 g/ml threshold level to view the PET images. SUV max, TLG and MTV were obtained from the 3D isocontour at 42% of the maximal pixel value (VOL42). PETCT data (Figs. 1 and 2) were measured from the region of interest (ROI) placed over the dominant sites (primary tumour site in preoperative staging cases, and the local recurrent sites or metastatic sites in postoperative suspected relapses).
Statistical analysis
Significant differences were found in the 18 F-FDG-PETCT parameters between patients who underwent 18 F-FDG-PETCT preoperatively or during the postoperative follow-up period, therefore subgroup analysis was performed in those patients who underwent 18 F-FDG-PETCT during their follow-up period. Categorical data were compared using the chi-square test and chi-square for linear association where appropriate. Continuous data were displayed as medians and ranges. These continuous data were compared using the MannWhitney U-test. Survival analysis was only performed in the group who underwent 18 F-FDG-PETCT during postoperative follow-up. Univariate and multivariate survival data were analysed using Cox's proportional hazards model. For survival analysis of 18 F-FDG-PETCT parameters, patients were grouped according by whether their values were above or below the median value. Variables associated with disease-specific survival at a significance level of P < 0.1 on univariate analysis were included in multivariate modelling using backward conditional regression where a two-sided P-value < 0.05 was considered statistically significant. Disease-specific survival was defined as time from date of 18 F-FDG-PETCT to the date of cancer-specific death. Statistical analyses were performed using IBM SPSS version 22 for Windows (Chicago, Illinois, USA). Two 
Results

Patients
A total of 103 patients were included in the study ( Table 1 ). The majority were men (57, 55%) over the age of 65 years (59, 57%) and with node-negative disease (53, 51%). Thirty-three (32%) patients underwent 18 higher SUVmax (17 vs 7, P < 0.001), higher SUVpeak (10 vs 5, P < 0.001), a higher MTV (8 ml vs 2 ml, P = 0.001) and higher TLG (90 g vs 10 g, P < 0.001) than recurrent lesions measured in patients during postoperative follow-up (Table 1) . A significantly higher proportion of patients who underwent 18 F-FDG-PETCT during preoperative staging had rectal cancer when compared with those who underwent 18 F-FDG-PETCT during follow-up (52% vs 29%, P = 0.024). However, there were no other statistically significant associations with demographic variables, including sex (P = 0.754), age (P = 0.415), body mass index (BMI) (P = 0.627), ASA grade (P = 0.480), smoking status (P = 0.921) or the pathology of the primary resected lesion, including T stage (P = 0.569), N (Table 2) .
Patients with NLR ≥ 5 at the time of 18 F-FDG-PETCT (n = 5) had a significantly higher median SUVmax (20 vs 7, P = 0.002), SUVpeak (14 vs 5, P < 0.001), MTV (29 ml vs 2 ml, P = 0.001) and TLG (338 g vs 9 g, P < 0.001) when compared with those patients with NLR < 5. However, NLR was not associated with demographic variables including sex (P = 0.794), age (P = 0.116), BMI (P = 0.595), ASA grade (P = 0.869), smoking status (P = 0.121), the pathology of the primary resected lesion, including tumour location (P = 0.602), T stage (P = 0.282), N stage (P = 0.247), differentiation (P = 0.735) and venous invasion (P = 0.199), or adjuvant chemotherapy prior to 18 F-FDG-PETCT (P = 0.059). Furthermore, when analysed at an NLR threshold of three, there was no association found between NLR and 18 F-FDG-PETCT parameters, demographic variables, pathology of primary lesion or adjuvant chemotherapy.
Association between 18 F-FDG-PETCT and mGPS in patients with suspected disease recurrence
Of the 70 patients who underwent 18 F-FDG-PETCT during follow-up after surgery, 59 had a mGPS measured prior to 18 F-FDG-PETCT (Table 3) . Patients with a mGPS of 1-2 at the time of 18 F-FDG-PETCT had a significantly higher median SUVmax (11 vs 6, P = 0.048), SUVpeak (8 vs 4, P = 0.046), MTV (13 ml vs 2 ml, P = 0.005) and TLG (146 g vs 8 g, P = 0.004) when compared with those patients with a mGPS of 0. However, mGPS was not associated with demographic variables including sex (P = 0.535), age (P = 0.727), BMI (P = 0.160), ASA grade (P = 0.402), smoking status (P = 0.989), the pathology of the primary resected Table 2 Relationship between neutrophil-lymphocyte ratio (NLR) and clinicopathological variables in patients who underwent 18 F-FDG-PETCT during follow-up after elective surgery for colorectal cancer (n = 68).
Characteristic All lesion, including tumour location (P = 0.545), T stage (P = 0.822), N stage (P = 0.871), differentiation (P = 0.183) and venous invasion (P = 0.378), or adjuvant chemotherapy prior to 18 F-FDG-PETCT (P = 0.458).
Survival
Of the 70 patients who underwent 18 F-FDG-PETCT during postoperative follow-up, the median follow-up period for patients alive at the time of their censoring was 25 months (range 8-78 months). There were 19 cancer-related deaths and four noncancer-related deaths. At univariate analysis (Table 4) there was an association between N stage (HR 4.78, 95% CI 1.58-14.43, P = 0.006), SUV peak (HR 3.01, 95% CI 1.21-7.48, P = 0.018) and TLG (HR 2.51, 95% CI 1.00-6.28, P = 0.049) with disease-specific survival at a significance level of P < 0.1. At multivariate analysis, only N stage (HR 4.05, 95% CI 1.32-12.41, P = 0.014) remained independently prognostic.
Discussion
The results of the present study show that 18 F-FDG-PETCT-derived markers of tumour metabolism in recurrent lesions are associated with systemic inflammation following elective surgery for colorectal cancer.
In the present study it was of interest that when compared with those patients who underwent 18 F-FDG-PETCT preoperatively, patients who underwent 18 F-FDG-PETCT during follow-up after elective surgery for colorectal cancer were more likely to have a lower SUVmax, SUVpeak, MTV and TLG. In the former, patient parameters were measured from the primary lesion. In the latter, however, parameters were measured from the dominant recurrent local or metastatic lesion. This may suggest that metastatic or recurrent lesions are metabolically less active than primary lesions. It may be that primary lesions are more established in terms of their supporting stroma and neovascularization than locally recurrent or metastatic lesions. Alternatively, adjuvant chemotherapy may play a role in diminishing the metabolism of metastatic or recurrent lesions, although the proportion of patients receiving systemic treatment prior to 18 F-FDG-PETCT in each cohort was similar. However, the size of the primary and recurrent lesions being compared was not formally measured. The significant difference in MTV between primary and secondary lesions suggests that the primary lesions were on average larger, which might itself be a confounding factor. Nevertheless, to our knowledge, no previous study has compared 18 F-FDG-PETCT measures of tumour metabolism in primary and metastatic or recurrent lesions in patients with colorectal cancer. The results of the present study suggest an association between systemic inflammation and 18 F-FDG-PETCT-derived measures of tumour metabolism in patients with recurrent colorectal cancer.
18
F-FDG-PETCT has been used to assess disease response and has been reported to be prognostic in patients with colorectal cancer [8] [9] [10] [11] ; however, very little prior work has been carried out in the context of systemic inflammatory response [13, 16] . To the authors' knowledge, this is the first study to directly examine the relationship between 18 F-FDG-PETCT parameters and measures of systemic inflammation in colorectal cancer.
The presence of systemic inflammation has been reported to be a negative prognostic factor in a variety of solid tumour types, including colorectal cancer [2] . Indeed, inflammation is now considered one of the hallmarks of cancer [17] . Furthermore, some consider inflammation to be a requirement for recurrence and metastasis. Therefore it is of great interest that the present study suggests that the metabolic activity of recurrent lesions is linked to host systemic inflammation. If this suggested direct relationship between the 18 F-FDG-PETCT-derived measures of tumour metabolism and the systemic inflammatory response were to be confirmed then this would shed new insight into the relationship between tumour and host processes.
F-fluorodeoxyglucose positron emission tomographycomputed tomography provides an estimate of glucose uptake of the entire lesion, which includes both cancer cells and the tumour microenvironment. The tumour microenvironment, composed of blood vessels, stroma and immune cells, supports tumour cell growth and spread and is an important factor in tumour development and outcomes in a number of solid organ cancers [17, 18] . The mechanism by which the tumour stroma facilitates tumour progression has not been fully elucidated; however, key theories include factors from the stroma influencing local inflammation, tumour pH and tumour metabolism. In addition to the proportion of stroma, the local inflammatory cell infiltrate is recognized to be prognostic in colorectal cancer [19] . It is possible that cytokines and other factors produced by the local inflammatory cells, which are related to local metabolic processes, also influence the host systemic inflammatory response [20] .
Furthermore, a recent observational study in patients with gastric cancer reported that FDG uptake by bone marrow was an independent prognostic factor, and that bone marrow PETCT parameters in these patients were associated with markers of the systemic inflammatory response including NLR and CRP [21] . The work by Lee and colleagues [21] may suggest that circulating inflammatory cells, as part of the systemic inflammatory response, have a direct effect on tumour metabolism. This observation is worthy of further investigation in patients with colorectal cancer. is not possible to comment on any relationship which might exist between the derived markers of tumour metabolism in primary lesions and then in subsequent recurrence within the same patient. However, the demographic, clinical and gross pathological features were similar across the two groups of patients. Given the significant relationship between the presence of systemic inflammation and 18 F-FDG-PETCTderived measures of tumour metabolism in recurrent lesions, it might be suggested that patients found to have a systemic inflammatory response during follow-up undergo 18 F-FDG-PETCT if standard follow-up CT and/or MRI imaging do not demonstrate any obvious recurrent disease. Furthermore, the results of the present study suggest that the addition of anti-inflammatory drugs to chemotherapy regimens in patients found to be systemically inflamed during follow-up may be of benefit by modulating tumour metabolism. Such changes to postsurgical follow-up and oncological treatments require evaluation in the context of a prospective trial with additional translational end-points. The main limitation of the present study is the relatively small number of patients, in particular those undergoing 18 F-FDG-PETCT preoperatively. This prevented meaningful survival analysis with regard to preoperative 18 F-FDG-PETCT parameters. Within those patients with suspected disease recurrence, the followup period for the cohort is at present relatively immature with a small number of events, therefore it is likely that both systemic inflammation and 18 F-FDG-PETCTderived measures of tumour metabolism have prognostic importance in this group of patients. In addition, due to the retrospective analysis of PETCT scans, no clinical data were available regarding potentially acute illness that may have confounded these scans. Furthermore, the retrospective nature of the study meant that not all patients had their CRP and white cell count measured at the time of 18 F-FDG-PETCT. The methodology meant that only lesion MTV and TLG and not that of the whole body was measured.
In conclusion, the present study reports a significant association between 18 F-FDG-PETCT measure of tumour metabolism in locally recurrent and metastatic colorectal cancer and systemic inflammation. It may be that tumour metabolism is one the driving mechanisms behind host systemic inflammation in solid tumours. Further work is required to fully characterize the relationship between the systemic inflammatory response and 18 F-FDG-PETCT findings in patients with colorectal cancer. However, the present results suggest that the systemic inflammatory response and 18 F-FDG-PETCT are complimentary in both the staging and follow-up of patients with colorectal cancer.
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